This is definitely good news, but it’s pretty clear from the release that this is not interim trial data. It’s based on patients who received through EAP only.
The FDA doesn't give EUAs based on EAP ("Compassionate Use") patient data; EUAs are based on placebo-control random clinical trial data. You already know that, I'm sure.